- Home
- SKLZ vs IGMS Comparison
SKLZ vs IGMS Comparison
Compare SKLZ & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKLZ
- IGMS
- Stock Information
- Founded
- SKLZ 2012
- IGMS 1993
- Country
- SKLZ United States
- IGMS United States
- Employees
- SKLZ N/A
- IGMS N/A
- Industry
- SKLZ EDP Services
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- SKLZ Technology
- IGMS Health Care
- Exchange
- SKLZ Nasdaq
- IGMS Nasdaq
- Market Cap
- SKLZ 80.3M
- IGMS 82.1M
- IPO Year
- SKLZ N/A
- IGMS 2019
- Fundamental
- Price
- SKLZ $6.29
- IGMS $1.27
- Analyst Decision
- SKLZ Buy
- IGMS Hold
- Analyst Count
- SKLZ 2
- IGMS 8
- Target Price
- SKLZ $10.75
- IGMS $6.14
- AVG Volume (30 Days)
- SKLZ 64.4K
- IGMS 173.6K
- Earning Date
- SKLZ 05-08-2025
- IGMS 05-13-2025
- Dividend Yield
- SKLZ N/A
- IGMS N/A
- EPS Growth
- SKLZ N/A
- IGMS N/A
- EPS
- SKLZ N/A
- IGMS N/A
- Revenue
- SKLZ $92,644,000.00
- IGMS $2,681,000.00
- Revenue This Year
- SKLZ $0.20
- IGMS $124.45
- Revenue Next Year
- SKLZ $14.10
- IGMS $45.07
- P/E Ratio
- SKLZ N/A
- IGMS N/A
- Revenue Growth
- SKLZ N/A
- IGMS 27.36
- 52 Week Low
- SKLZ $3.54
- IGMS $0.92
- 52 Week High
- SKLZ $7.48
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- SKLZ 61.43
- IGMS 52.80
- Support Level
- SKLZ $6.14
- IGMS $1.13
- Resistance Level
- SKLZ $6.46
- IGMS $1.42
- Average True Range (ATR)
- SKLZ 0.32
- IGMS 0.09
- MACD
- SKLZ -0.03
- IGMS 0.01
- Stochastic Oscillator
- SKLZ 59.49
- IGMS 55.88
About SKLZ Skillz Inc.
Skillz Inc is a mobile game development company. It is engaged in re-inventing competitive mobile gaming and thereby expanding the mobile gaming market. Some of the games available on its platform are Dominoes Gold, Blackout Bingo, 21 Blitz, and Solitaire Cube among others. The company's reportable business segments are; the Skillz segment and the Aarki segment. The majority of its revenue is generated from the Skillz segment which is an eSports gaming platform, enabling game developers to monetize their content through multi-player competition. Geographically, the company derives its key revenue from the United States and the rest from Israel, China, Malta, and other countries.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.